SLS - SELLAS Life Sciences Group, Inc.
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. ("Sellas" or the "Company") (NASDAQ: SLS).
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. (“Sellas” or the “Company”) (NASDAQ: SLS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Power Metallic Defines High-Grade Maiden Resource at Lion Averaging ~3.9% CuEq, with >85% Indicated and Significant Expansion Potential
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. ("Sellas" or the "Company") (NASDAQ: SLS).
- Three posters to highlight preclinical activity of SLS009 (tambiciclib) across patient-derived KRAS mutant organoid models of pancreatic cancer – - Studies conducted in collaboration with the University of Wisconsin School of Medicine and Public Health - NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that three abstracts evaluating SLS009 (tambiciclib), a potent, selective CDK9 inhibitor, in preclinical models of pancreatic ductal adenocarcinoma (PDAC) have been accepted for poster presentation at the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development.
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of SELLAS Life Sciences Group, Inc. (“Sellas” or the “Company”) (NASDAQ: SLS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
SELLAS Life Sciences Group Inc. (NASDAQ:SLS) stock is trading higher on Thursday. Year-to-date, the stock has surged by around 300%.
SELLAS Life Sciences Group is a high-conviction buy ahead of the pivotal Phase 3 REGAL trial readout for GPS in AML. The unusually long REGAL trial timeline suggests GPS may be delivering a meaningful survival benefit in a high-unmet-need AML population. SLS is well-funded into 2027, with $138.3 million in cash and targeted spending aligned to upcoming binary catalysts.
- Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80 th Event - - 28 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Topline Data Expected in Q4 2026 - - Strong Preclinical Indications of Efficacy of SLS009 in Advanced Pancreatic Cancer Resistant to RAS inhibitors, Clinical Development Preparations Ongoing - - $138.3 Million in Cash and Cash Equivalents as of June 30, 2026 - NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. “The second quarter was an important period of execution for SELLAS as we continued to advance both of our lead clinical programs, GPS and SLS009,” said Angelos Stergiou, MD, ScD h.c.
SELLAS Life Sciences enters its pivotal REGAL readout with a transformed shareholder base, stronger balance sheet, and a new supply structure. Institutional ownership doubled to 36.34%, with average allocation rising, reflecting both new and existing holders increasing stakes ahead of the binary event. Passive and index-linked funds now dominate SLS's register, while multi-strategy and quant funds have exited, reducing volatility-driven trading around the catalyst.
SELLAS Life Sciences is at the center of a debate over its event-driven Phase 3 REGAL trial for GPS in AML CR2 patients. The extended REGAL timeline should not be interpreted as evidence of failure or success, given its event-driven design and recent protocol amendments. FDA-approved unlimited dosing and continued management confidence add nuance, but only final data will determine REGAL's outcome.
SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares are trading lower Wednesday as investors take profits following the stock's strong longer-term uptrend, with broader risk appetite also softer across equities.
SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares are trading lower Tuesday as traders digest the recent breakout run and early profit-taking shows up even with momentum still elevated from the company's latest corporate update.
[url="]Amentum[/url] (NYSE: AMTM), a global leader in advanced engineering and technology solutions, has been awarded NASA's Consolidated Spaceflight Mission O
SELLAS Life Sciences is advancing a dual-path AML franchise with GPS nearing pivotal Phase 3 REGAL readout and SLS009 progressing in high-risk AML settings. SLS has strengthened its cash position to $135.8 million, providing a multi-year runway and flexibility ahead of critical data and potential commercialization. The REGAL trial's delayed event count sustains optimism for GPS efficacy in CR2 AML, with topline results imminent and BLA preparation underway.
Sellas Life Sciences (SLS) shares are extending gains on Jun. 26 following a key regulatory filing that disclosed a series of comprehensive corporate amendments regarding executive compensation and protection. Specifically, the board restructured change-of-control and severance agreements for CEO Angelos Stergiou, CFO John Burns, and CDO Dragan Cicic.
SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares are pushing higher Friday morning, adding to Thursday's strong rally.
Shares of SELLAS Life Sciences Group Inc. (NASDAQ:SLS) are rallying sharply Thursday, hitting a fresh 52-week high of $11.06, up over 16% in midday trading. The clinical-stage biopharmaceutical company is experiencing a massive surge in volume following a regulatory filing.
Sellas Life Sciences Group Inc (NASDAQ:SLS) shares are trading higher on Wednesday as traders react to the company's latest update on its acute myeloid leukemia pipeline and the timeline for a pivotal Phase 3 readout. Here's what investors need to know.
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, will participate in the following upcoming investor conferences: 2026 Stifel Virtual Targeted Oncology Forum Format: Corporate Presentation and Fireside Chat Date and Time: Tuesday, May 19, 2026, at 2:00 PM ET Location: New York, NY Webcast Link: Click here A.G.P.